Erbitux MEtastatic Colorectal Cancer Strategy Study
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
- To investigate whether cetuximab alone (given until progression or cumulative toxicity)
after 8 cycles of FOLFIRI + cetuximab results in a non inferior Progression Free
Survival when compared with continuous FOLFIRI + cetuximab (given until progression or
cumulative toxicity).
- To assess whether an improvement in the incidence of grade 3-4 hematological and
non-hematological adverse events (AEs) can be achieved in the experimental arm
(cetuximab alone after 8 cycles FOLFIRI + cetuximab) as compared to the continuous
chemotherapy arm (FOLFIRI plus cetuximab)
- To explore the possibility of using liquid biopsies for molecular profiling as well as
monitoring treatment activity in mCRC pts receiving cetuximab based therapy